MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Stroh J, Seckinger A, Heider M, Rudelius M, Eichner R, Schick M, Slawska J, Emde-Rajaratnam M, Salwender H, Bertsch U, Goldschmidt H, Weisel K, Scheid C, Keller U, Hose D, Bassermann F.
Stroh J, et al. Among authors: salwender h.
Blood Adv. 2022 Jan 25;6(2):515-520. doi: 10.1182/bloodadvances.2021005532.
Blood Adv. 2022.
PMID: 34768284
Free PMC article.